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Abstract 
Background: The prognosis of patients with progressive meningioma after failure of surgery 
and radiotherapy is poor. 
Methods: We retrospectively evaluated the safety and efficacy of somatostatin-receptor 
(SSTR)-targeted radionuclide therapy (177Lu-DOTATATE (n=16), 90Y-DOTATOC (n=3), or 
both (n=1) in patients with progressive, treatment-refractory meningiomas (5 WHO grade I, 7 
WHO grade II, 8 WHO grade III) and in part multifocal disease (17 of 20 patients). 
Results: SSTR radionuclide treatment (median of 3 treatment cycles, median administered 
dose/cycle 7,400 MBq) led to a disease stabilization in 10 of 20 patients for a median time of 
17 months. Stratification according to WHO grade showed a median progression-free survival 
(PFS) of 32.2 months for grade I tumors, 7.2 for grade II, and 2.1 for grade III. PFS at 6 
months was 100% for grade I, 57% for grade II, and 0% for grade III. Median overall survival 
was 17.2 months in WHO grade III patients and not reached for WHO I and II at a median 
follow-up of 20 months. In the analysis of single meningioma lesions, maximal and mean 
standardized uptake values in pretherapeutic 68Ga-DOTATOC/-TATE-PET/CT were 
significantly higher in those lesions with radiographic stability after 6 months. In line with 
this, high expression of SSTR via immunohistochemistry was associated with PFS > 6 
months.  
Conclusions: SSTR-targeted radionuclide treatment has activity in a subset of patients with 
meningioma. Expression of SSTR via immunohistochemistry or radionuclide uptake might 
serve a predictive biomarker for outcome to facilitate individualized treatment optimization in 
patients with uni- and multifocal meningiomas. 
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Background 
Meningiomas are the most common primary brain tumors in the central brain tumor registry 
of the US (CBTRUS, 2008-2012)1. According to the World Health Organization (WHO), 
meningiomas are classified into grade I (benign meningioma), grade II (atypical meningioma) 
and grade III (anaplastic meningioma) categories2. Surgical resection is the standard of care. 
Usually, adjuvant treatment is not needed for long-lasting tumor control, particularly in WHO 
grade I meningiomas. Patients with WHO grade II and grade III meningiomas, especially in 
case of incomplete resection, commonly receive adjuvant radiotherapy. However, a subgroup 
of patients, particularly with high grade meningiomas, show highly aggressive tumor growth 
despite repeated surgical resections and radiotherapy. There is no standard of care beyond 
surgery and radiotherapy in progressive meningioma. A meta-analysis of 47 publications on 
medical therapy for progressive meningioma showed that this subgroup of patients exhibits a 
very poor prognosis: weighted average progression-free survival at 6 months (PFS-6) was 
29% for WHO grade I meningioma and 26% for WHO grade II/III meningioma3. 
Radiographic response beyond disease stabilization is rarely reported in these studies with 
partial response rates below 3% and complete response below 1%3. There have been several 
attempts to treat small cohorts with cytotoxic chemotherapy and targeted therapy; however, 
these studies largely failed to show substantial therapeutic benefit4-7. Some activity was 
recently attributed to anti-angiogenic agents such as bevacizumab and sunitinib, however, 
PFS-6 rates still were below 50%8,9. Somatostatin receptors (SSTR) overexpressed in 
meningiomas have been proposed as a therapeutic target for systemic treatment10. However, 
somatostatin analogs have shown only limited efficacy in retrospective series and phase II 
studies11-13. DOTA-D-Phe1-Tyr3-octreotide (DOTATOC) and DOTA-D-Phe1-Tyr3-
octreotate (DOTATATE) are agents with a chelator-site (DOTA) and a binding site to 
somatostatin receptors (octreotide and octreotate, respectively). It is feasible to label the 
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chelator site with β+ emitting gallium-68 (68Ga) for PET diagnostic purposes or with β- 
emitting radioisotopes yttrium-90 (90Y) and lutetium-177 (177Lu) for therapeutic purposes. 
The therapeutic radionuclides deliver SSTR-targeted β--radiation within a few millimeters 
distance of the binding site14,15, in contrast to biochemical receptor interference as proposed 
for somatostatin analogs (e.g., octreotide, pasireotide). Radionuclides binding to SSTR have 
shown efficacy in neuroendocrine tumors16; however, little is known about the efficacy of this 
treatment for SSTR-positive meningiomas especially in highly pretreated populations17-21. 
We here studied the safety and efficacy of SSTR-based radionuclide therapy for patients with 
meningiomas that progressed after several lines of therapy. In addition, we analyzed whether 
the intensity of SSTR expression or tracer uptake in the pretherapeutic 68Ga-DOTATATE/-
TOC positron emission tomography (PET) scans are associated with therapeutic efficacy. 
 
Patients and methods 
Patients and histology 
We reviewed the clinical records of 20 consecutive meningioma patients who underwent 
SSTR-based radionuclide therapy for progressive disease between 2009 and 2015 at the 
University Hospital of Zurich (n=11, 3 of them were sent to the University Hospital of Basel 
for radionuclide treatment) and the University Hospital of Munich (n=9). Approval for the 
retrospective analysis was obtained from the local ethics committees or was not required 
according to local regulations. Histological grading and histological subtyping of the most 
recent available histological samples were performed at the sites according to the WHO 
classification 20072. The time interval between resection of lesions and radionuclide therapy 
varied between 1 and 97 months (median 13 months). SSTR-type-2 (SSTR-2) expression 
assessed by immunohistochemistry was available in 18 of 20 patients. Deparaffinized tissue 
sections were immunostained for SSTR-2 (SS-800, Gramsch Laboratories, Schwabhausen, 
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Germany) followed by nuclear counterstaining with Mayer hemalaun. SSTR-2 expression was 
scored as grade 1 (no/weak), grade 2 (mild/modest), grade 3 (moderate) and grade 4 (strong) 
by board-certified neuropathologists (ER, US); representative images are shown in 
Supplementary Figure 1. 
Treatment 
Radionuclide therapy was delivered with the somatostatin analog DOTATATE labeled with 
177Lu (n=16) or DOTATOC labeled with 90Y (n=3), or both (n=1), depending on local 
availability. Treatment was administered intravenously in cycles of minimal 3,400 MBq and 
maximal 7,648 MBq per cycle for a maximum of 4 cycles. Co-therapeutic agents commonly 
included steroids, antiemetics and infusion of solutions containing 0.25% lysine/arginine for 
renal protection in line with previous studies evaluating SSTR-based radionuclide therapy16,17. 
Toxicity 
The assessment of adverse events related to radionuclide therapy was restricted to the period 
from the beginning of treatment until 3 months after the last cycle. Data were collected 
retrospectively using Common Terminology Criteria (CTC) for Adverse Events (version 4.0). 
Radionuclide imaging 
Patients received pretherapeutic PET/CT with 68Ga-DOTATATE/-TOC (n=17) or indium-
111(111In)-octreotide scintigraphy (n=3), confirming the expression of SSTRs prior to therapy. 
Acquisition of imaging data was performed according to current local conventions and 
infrastructure. 111In-octreotide scintigraphy was performed to qualitatively document 
pretherapeutic receptor expression but was not suitable for quantitative analysis. Quantitative 
lesion-specific analysis of uptake characteristics was done for those patients with available 
68Ga-DOTATATE/-TOC-PET-CT scans. The intensity of uptake in single and multiple 
(visually separate) meningiomas was characterized by maximal and mean standardized uptake 
value (SUVmax and SUVmean ) on 68Ga-DOTATATE/-TOC PET/CT by a board-certified 
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nuclear medicine physician. For analysis of these parameters, a semi-automatic volume of 
interest (VOI) was drawn using a threshold of 2.3, which was previously shown to 
discriminate meningioma from tumor-free tissue22. In the case of tracer uptake below a 
threshold of 2.3, SUVmax was assessed automatically by using an autocontour VOI. To 
account for differences in imaging parameters depending on local acquisition procedures, 
analyses were done both pooled and separately for the centers. 
Assessment of response and survival 
Since there is no consensus on response criteria for meningioma, we adapted the Macdonald 
criteria for malignant glioma to assess the response23. In brief, bidimensional measurements 
were performed on Gadolinium-enhancing areas of T1-weighted MRI images for 16 of 20 
patients. In 4 patients, contrast-enhanced high resolution CT images were used depending on 
imaging availability. MRI or CT scans were available with a median of 1.1 months prior to 
therapy and the next subsequent imaging with a median of 3.8 months after the first cycle of 
radionuclide treatment.  Complete response was defined by complete disappearance of the 
tumor and partial response by a more than 50% reduction of tumor size. Stable disease was 
recorded when there was less than 50% decrease or up to 25% increase in size at least 4 
weeks after initiation of treatment. Progressive disease was defined either by an increase of 
more than 25% of tumor size, the appearance of new lesions, clinical decline or death. In 
subjects with multiple lesions, progression in any of the lesions of more than 25% or increase 
of total tumor load of more than 25% was considered as progression. 
Where applicable, depending on the quality of available digital MRI, tumor load was 
additionally measured by 3-D-volumetric analysis with PMOD software Version 3.4 (PMOD 
Technologies, Zurich, Switzerland). The baseline MRI as reference for the relative change of 
tumor volume was defined as the last MRI before radionuclide treatment. The pre- and 
posttherapeutic growth rate was estimated using Microsoft Excel 2010 (Redmont, WA, USA) 
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and defined as the slope of a linear regression trend line of the percentage of pre- and 
posttherapeutic tumor volumes in relation to the baseline tumor volume (variable y) and 
corresponding days before and after radionuclide treatment (variable x). In the case of 
surgical resection or embolization during the interval of volumetric analysis, data points were 
analyzed separately before and after the interventions.  
Statistics 
Progression-free survival (PFS) and overall survival (OS) rates were calculated from the first 
dose of radionuclide until progression and death, respectively. Five patients did not show any 
tumor progression and 13 patients were alive before the cut-off date (31st of March 2015). 
These patients were censored at the last date of contact. For the calculation of PFS at 6 
months (PFS-6) and OS at 12 months (OS-12), a single patient was excluded due to 
insufficient follow-up. For the additional lesion-based analysis, the calculation of the 
progression-free time interval of each single meningioma lesion was performed analogous to 
the patient-based analysis. 
Kaplan-Meier estimation was applied for the calculation of median PFS, median duration of 
best response, OS and median follow-up. Non-parametric statistics were applied using 
Spearman correlation coefficient, Mann-Whitney-test and binary logistic regression analysis 
where indicated (GraphPad Prism software version 5.0 (San Diego, CA, USA), SPSS 
software version 22 (Ehningen, Germany).  
 
Results 
Study population and pretreatment characteristics 
Patient and pretreatment characteristics are summarized in Table 1, with individual patient 
characteristics provided in Supplementary Table 1. A total of 20 patients were identified, with 
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11 patients initially diagnosed with WHO grade I meningioma and 9 patients with WHO 
grade II meningioma. The histological grade of recurrent tumors was higher prior to 
radionuclide therapy in 10 patients and lower in 1 patient, with overall 5 WHO grade I, 7 
WHO grade II and 8 WHO grade III meningiomas. The most common histological 
meningioma subtype at diagnosis was meningothelial (n=8) and prior to radionuclide therapy 
atypical (n=6). Prior to radionuclide therapy, all patients had documented radiographic 
progression. Eighty-five percent of the patients had multiple intracranial meningiomas and 
20% had extracranial disease. All but one patient underwent repeated surgery with a median 
number of 3 surgical resections and 40% of patients had been previously treated with at least 
one embolization. All but 2 patients had previously received radiotherapy for meningioma 
including one line of radiotherapy in 11 patients, 2 lines in 5 patients and 3 in 2 patients. 
Beyond conventional radiotherapy, stereotactic radiotherapy was applied in 4 patients and 
stereotactic radiosurgery (Gamma Knife) in 2 patients (Supplementary Table 1). 
The median time of radiotherapy to SSTR based radionuclide therapy was 2.9 years (range 
1.3-14.3 years). Four patients were treated with radiotherapy due to preexisting conditions 
prior to the diagnosis of meningioma; 30% had received at least one line of chemotherapy. 
Agents used included hydroxyurea, long-acting somatostatin analogs, sorafenib or 
bevacizumab, alone or in combination with etoposide or doxorubicin. The median time from 
diagnosis to the start of radionuclide treatment was 10 years.  
Treatment 
Eighteen patients were treated with radionuclide therapy alone, and 2 patients received 
combination treatment. One patient with WHO grade II meningioma underwent embolization 
immediately prior to radionuclide treatment. One patient with WHO grade III meningioma 
received interferon-α-2a in addition as de-novo combination treatment (Supplementary Table 
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1). The median number of treatment cycles was 3 with a median single dose of 7,400 MBq 
and median cumulative dose of 20,153 MBq (interquartile range 13,665-27,593 MBq).  
Toxicity 
Radionuclide monotherapy was generally well tolerated. Adverse events as assessable 
retrospectively are summarized in Supplementary Table 2. Lymphocytopenia affected  70% 
of patients, including severe lymphocytopenia in 30% of patients (25% grade 3, 5% grade 4, 
15% persistent grade 3/4 lymphocytopenia). The severity of lymphocytopenia correlated with 
the number of previous systemic chemotherapic agents (Spearman correlation r=0.56, 
p=0.01). 
Response and outcome 
Table 2 and Figure 1 summarize data on response, PFS and OS. None of the patients achieved 
complete or partial response as assessed by modified Macdonald criteria. In 50% of patients, 
radionuclide treatment led to stable disease. The median duration of disease stabilization was 
17 months. All patients with WHO grade I meningioma responded with stable disease, while 
the percentage was lower in WHO grade II (57%) or WHO grade III (13%) meningioma. In 4 
of 17 patients with multiple lesions, we observed variable intraindividual tumor responses. 
Median PFS was 5.4 months for all patients pooled (Figure 1A). PFS was not significantly 
different between WHO I and WHO II meningiomas, in contrast to WHO I and WHO III as 
well as WHO II and WHO III meningiomas (p<0.05, log-rank/Mantel-Cox test, Figure 1B). 
Median OS for all patients was not reached with a median follow-up of 20 months (Figure 
1C). For patients with WHO grade III meningioma, median OS was 17.2 months. Statistically 
significant differences between WHO grades were not reached with the limitation of 13 
censored, i.e., living subjects at time of analysis (Figure 1D). 
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In addition to formal response assessment, we quantified tumor growth rate by 3-D 
volumetric analysis in a subset of 8 patients, tabulated in Supplementary Table 1. Two 
patients with WHO grade I, 1 with WHO grade II, and 5 with WHO grade III tumors had 
appropriate digital MRI documentation available. Figure 2 confirms progressive tumor growth 
before radionuclide therapy in these patients. Growth rate was reduced by 25% or more after 
radionuclide therapy in 4 of 8 patients. Patients lacking a reduction of growth rate by 25% or 
more or with accelerated growth suffered from WHO grade II (1 patient) or WHO grade III 
meningioma (3 patients).  
In a previous patient-based analysis, high SSTR radionuclide uptake as assessed by visual 
scoring was shown to correlate with survival after SSTR-based radionuclide therapy17. We 
extended this approach and analyzed single meningioma lesions for SUVmax and SUVmean and 
correlated these parameters with therapy failure, i.e. progression within 6 or 12 months as a 
binary variable, and with PFS as a continuous variable. Higher uptake of radionuclide 
(SUVmax and SUVmean) was associated with longer PFS (Spearman correlation r=0.37, 
p=0.0003 and r=0.34, p=0.0024 respectively). Progression of single lesions within 6 months 
or 12 months correlated inversely with higher SUVmax and SUVmean (Spearman correlation r=-
0.53 for 6 months, r=-0.57, for 12 months and r=-0.51 for 6 and 12 months, p<0.0001 
respectively). SUVmax correlated with SUVmean (Spearman correlation r=0.96, p<0.0001). 
Single lesion analysis in pretherapeutic PET elicited lower SUVmax and SUVmean in lesions 
that progressed at 6 months, i.e. SUV was higher in stable lesions (Mann-Whitney-test, 
p<0.0001, Figure 3A, B). Similar results were obtained within single centers, however due to 
low statistical power not reported here.  
SUVmax and SUVmean were lower in WHO grade III meningiomas compared with WHO 
grade I or II meningiomas (Mann-Whitney-test, p<0.001 and p<0.05). However, SUVmax or 
 13 
 
SUVmean did not significantly differ in WHO grade I and WHO grade II meningiomas (Figure 
3C, D).  
To investigate the association of SUV with outcome independent of WHO grade, we 
separately analyzed meningiomas of different WHO grade and performed multivariate 
regression analysis. Here we assumed that in patients with multiple lesions, the WHO grade 
of one lesion was representative for all lesions. For WHO grade I meningiomas, none of the 
lesions progressed over 6 months, thus not permitting this analysis. In WHO grade II 
meningiomas, SUVmax and SUVmean were significantly lower in those lesions that progressed 
at 6 months (Mann-Whitney-test, p<0.01). The same trend was seen for WHO grade III 
meningiomas, although significance was not reached (Figure 3E, F). Lesion-specific analysis 
for progression at 12 months (data not shown) was comparable to the analysis of lesions at 6 
months (as illustrated in Figure 3). 
In multivariate regression analysis, low SUVmean and high WHO grade were independent 
parameters associated with progression of lesions within 6 months (Binary logistic regression, 
odds ratio (OR) 0.275, p=0.023, and OR 35.693, p=0.002, respectively).  
We next asked whether SSTR expression in tumor tissue (Supplementary Table 1) as assessed 
by immunohistochemistry correlated with patient outcome. Comparative lesion-specific 
analysis was not possible in this retrospective study, because, although patients frequently 
suffered from multiple lesions, most commonly only single lesions were resected. Higher 
SSTR expression in tumor tissue was associated with stable disease after radionuclide 
treatment at 6 months (Spearman correlation r=0.50, p=0.04). No patient with grade 1 
(no/weak) SSTR expression level (5 of 18 patients, 4 of these 5 patients suffering from WHO 
grade III meningioma) had stable disease within 6 months. SSTR expression was not 
correlated to WHO grade (Spearman r=-0.36, p=0.15). 
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Discussion 
This study confirms and extends current knowledge on SSTR-targeted radionuclide therapy 
(177Lu-DOTATATE/90Y-DOTATOC) for progressive meningiomas, providing evidence that 
SSTR radionuclide uptake (SUVmax and SUVmean) and SSTR immunoexpression could serve 
as biomarkers for benefit from treatment. On the basis of a lesion-based analysis of SUV and 
outcome, lesions that are more likely to be stable after SSTR-targeted treatment could be 
identified. This innovative approach may facilitate optimization of individualized and lesion-
tailored therapy in patients with uni- and multifocal meningiomas, especially in treatment 
refractory situations. 
Our cohort consists of heavily pretreated patients after failure of standard therapeutic options 
receiving systemic therapy for progressive disease. Despite the poor prognosis of patients 
with progressive meningioma with PFS-6 rates of 29% for WHO grade I and of 26% of WHO 
grade II and grade III meningiomas in historical controls derived from a meta-analysis of 47 
studies3, radionuclide therapy resulted in disease stabilization in 10 of 20 patients for a 
median of 17 months. PFS-6 rates of patients with WHO grade I (100%) and grade II tumors 
(57%) were higher than in these historical controls, in contrast to poor outcome of WHO 
grade III tumors (0%). All patients had documented progressive tumor growth before 
initiating radionuclide therapy. This is especially evident in the volumetric analysis, showing 
a reduction of the growth dynamics in 50% of patients analyzed (Figure 2). Still, differences 
in PFS, predominantly in patients with lower WHO grade tumors and documented stable 
disease as best response, may in part reflect the natural course of the disease. 
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Evidence of SSTR-based radionuclide therapy is still limited. Previous studies, mostly in 
small and heterogeneous cohorts with limited data on WHO grade, report similar response 
rates as our study (Table 3). Higher response rates were achieved in one study with a less 
pretreated patient population18 and one study lacking an intention-to-treat-analysis20. 
Response assessments were different between the studies, pointing towards a need for 
standardized response criteria to design clinical trials for comparable results. PFS-6 rate was 
analyzed in only one trial, showing similar results with 46%19 versus 42% in our cohort. OS 
was assessed in 2 of 5 studies. The mean OS of 8.6 years in one cohort17 is difficult to 
compare with the median OS of 40 months in another cohort19 due to different statistic 
measures. In our study, median OS from radionuclide therapy was not reached at a median 
follow-up time of 20 months. 
In line with previous data, SSTR-based radionuclide therapy was well tolerated. However, the 
high incidence of lymphocytopenia should be considered, especially with patients receiving 
additional immunosuppressive medications and who underwent previous cytotoxic 
chemotherapy. The higher number of grade 3/4 lymphocytopenia compared to previous 
studies may be either due to pretreatment characteristics with cytotoxic chemotherapy in our 
study or the lack of detailed analysis of white blood cell differential counts in previous 
studies.  
In contrast to previous studies, we undertook a lesion-specific approach hypothesizing that 
radionuclide uptake, especially the SUVmean, may represent a lesion-specific biomarker for 
benefit of treatment with SSTR radionuclides. This is in line with the concept that high tracer 
uptake in diagnostic PET results in high radiation dose in therapy24. Since none of the patients 
and none of the individual lesions showed a complete or partial response as defined by 
Macdonald criteria, and since short PFS intervals are difficult to interpret considering the 
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natural course of the disease, we chose lesion stability or progression at 6 months as a 
surrogate marker for response to radionuclide therapy and performed subgroup analysis 
according to different WHO grades. The finding that lesions that failed to progress within 6 
months exhibit higher SUVmax or SUVmean (Figure 3A, B) may be useful for clinical decision-
making in patients with multiple meningiomas, by identifying lesions with a higher or lower 
probability of response. This observation holds true when analyzed separately for WHO grade 
II meningiomas; however, it was not evaluable for WHO grade I meningiomas due to the lack 
of progression over 6 months (Figure 3E, F). For WHO grade III meningiomas, radionuclide 
uptake may represent a less powerful biomarker for stability of lesions over 6 months, since 
the respective subgroup analysis failed statistical significance, however, potentially limited 
due to small sample size (Figure 3E, F). The relatively low radionuclide uptake of WHO 
grade III meningiomas in our cohort might at least in part contribute to poor PFS-6 in 
comparison to historical controls3. 
Multivariate analysis in our cohort of PET parameters and outcome measures via logistic 
regression analysis identified high SUVmean and low WHO grade as independent parameters 
associated with lesion stability at 6 months. Hence, SUVmean might represent a biomarker with 
prognostic and/or predictive value identifying lesions likely to respond to SSTR treatment. 
The hypothesis of SUVmean as a predictive biomarker can be relatively supported by the fact 
that the intensity of SSTR by immunohistochemistry correlated with PFS at 6 months but not 
with WHO grade. In the literature, there are few data on SSTR expression and tumor cell 
proliferation in meningioma. In vitro, both an antiproliferative and a growth stimulatory role 
were attributed to SSTR expression25,26. In a previous study, SUVmax and SSTR expression 
via immunohistochemistry were highly correlated in surgical specimens while SUVmax did 
not correlate with WHO grade22. In our data set, SUVmax or SUVmean were not significantly 
different in lesions of WHO grade I or grade II while WHO grade III tumors exhibited lower 
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SUVmax and SUVmean (Figure 3C,D). Another study suggested that meningioma growth 
correlated with SSTR expression in WHO grade I and II meningiomas as measured with 68Ga-
DOTATATE PET but not in grade III meningiomas, pointing towards an escape strategy from 
SSTR dependence of meningioma growth in de-differentiated meningioma27. 
In conclusion, there is evidence that radionuclide uptake and intensity of SSTR expression 
might represent predictive biomarkers for benefit of radionuclide treatment. However, due to 
the lack of prospective clinical data and the relatively low patient numbers in our study, 
confirmation of this hypothesis and identification of reliable cut-off values of SUV requires a 
prospective controlled clinical trial with standardized pre- and posttherapeutic Ga68-
DOTATATE/-TOC PET-CT. 
Based on our findings, we suggest a lesion-based therapeutic concept for tailoring therapeutic 
options in patients with multiple meningiomas. This approach is supported by our observation 
that a subgroup of patients showed variable intraindividual tumor responses. Lesions with 
lower radionuclide uptake should be subjected to surgery or possibly radiotherapy rather than 
SSTR radionuclide therapy. In contrast, if a target lesion exhibits high radionuclide uptake, 
SSTR radionuclide therapy might be a more reasonable therapeutic option. In addition, 
radionuclide therapy could be considered in early disease, prior to a potential malignant 
progression, since WHO grade III tumors might less likely show a benefit.  
A previous study proposed a SUVmax of 2.3 as a reliable discriminator between meningioma 
and tumor-free tissues (90.1% sensitivity, 73.5% specificity, and 89.0% positive predictive 
value)22. In our cohort, a SUVmax of less than 2.3 was in some cases, associated with lesion 
stability but excessive tumor growth in others despite radionuclide therapy. This indicates that 
a lesion with a SUVmax of less than 2.3 might represent tumor-free tissue with the previously 
reported sensitivity of 90.1%, however might also be active tumor not likely to respond to 
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SSTR therapy. For the final identification of target lesions with a SUVmax of less than 2.3 to 
be active tumor tissue, surgery may be warranted. 
The limitations of this analysis include the fact that SSTR immunolabeling and pretherapeutic 
PET imaging were not available for the entire patient cohort, the relatively long time interval 
between histological assessment of SSTR immunolabeling and radionuclide therapy and the 
assumption that the WHO grade of the resected lesion is representative of the whole tumor 
load. Other limitations encompass the retrospective study design, the likely underestimation 
of toxicity common to all retrospective assessments, the difficulty in identifying delayed 
toxicity attributable to treatment beyond the arbitrarily chosen cutoff of three months, 
inhomogeneous patient cohort and diagnostic and treatment protocols. Still, despite this 
obvious heterogeneity in our data set, we identified the link of higher SUV indicating benefit 
of treatment relatively arguing for a robust association.  
In conclusion, there is evidence that SSTR radionuclide therapy has activity in patients with 
WHO grade I and grade II meningiomas progressing after standard therapy, especially in 
cases of high SSTR expression as measured by DOTATATE/-TOC PET-CT or 
immunohistochemistry. However, the efficacy in WHO grade III meningiomas remains 
uncertain. Further prospective and randomized trial data and standardized response 
assessments will be needed to optimally evaluate the role of radionuclide therapy as a 
systemic therapeutic option in meningioma. For validation of the role of SUVmean as a 
predictive lesion-specific biomarker, a prospective trial based on the radionuclide uptake 
profile is warranted. 
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Figure 1: Progression-free and overall survival 
Progression-free survival (PFS) and overall survival (OS) Kaplan Meier curves for all patients 
pooled (n=20, A and C), and differentiated by WHO grade (B and D)  
 
Figure 2: Volumetric analysis before and after administration of radionuclide therapy 
Changes in tumor volume as assessed by MRI volumetric analysis were analyzed before and 
after radionuclide treatment in 8 patients (A-H). Individual patient characteristics are 
available in Supplementary Table 1. Growth rate was estimated as the slope of a linear 
regression trend line of the percentage of tumor volume related to the baseline MRI before the 
first cycle of radionuclide (variable y) and days before and after radionuclide treatment on day 
0 (variable x). Cycles of radionuclide treatment, surgical resections or embolizations during 
the time intervals of volumetric analysis were depicted with arrows as indicated. Data points 
for calculation of growth rate before and after the respective interventions were analyzed 
separately.  
 
Figure 3: Lesion-specific analysis stratified by SUV and WHO grade 
Meningioma lesions, progression-free less than 6 months (PF<6) or more than 6 months 
(PF>6), were compared for SUVmax (A) and SUVmean (B). Lesions were grouped according to 
WHO grade and analyzed for SUVmax (C) and SUVmean (D). Meningioma lesions (PF<6 
versus PF>6 months) were analyzed separately for WHO grade regarding their SUVmax (E) 
and SUVmean (F). Each circle represents a single meningioma, different colors represent data 
acquired from different centers. Median and interquartile ranges are shown. Statistical 
 25 
 
comparison was done with Mann-Whitney test (*p<0.05, **p<0.001, ***p<0.0001, ns: not 
significant). 
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Table 1: Patient and pretreatment characteristics 
Meningioma grade I II III 
- at diagnosis, n [%] 11 
[55%] 
9 [45%] 0 [0%] 
- at surgery for recurrence, n [%] 5 [25%] 7 [35%] 8 [40%] 
Age, median [range] 43 [18-67] 
Gender  
Male, n [%] 9 [45%] 
Female, n [%] 11 [55%] 
Median KPS prior to 177Lu-DOTATATE/90Y-
DOTATOC  [range] 
75 [40-100] 
Multiple meningiomas 
- at diagnosis, n [%] 
- prior to radionuclide therapy, n [%] 
 
4 [20%] 
17 [85%] 
Extent of resection at diagnosis  
Complete resection, n [%] 12 [60%] 
Partial resection, n [%] 6 [30%] 
No data available, n [%] 2 [10%] 
Surgical resections prior to 177Lu-DOTATATE/90Y-
DOTATOC, median [range] 
3 [1-7] 
Surgical resections after 177Lu-DOTATATE/90Y-
DOTATOC   
- number of patients, n [%] 
- median number of surgeries [range] 
 
7 [35%] 
0 [0-2] 
Angiographic embolizations prior to 177Lu-
DOTATATE/90Y-DOTATOC   
- number of patients, n [%] 
 
8 [40%] 
Radiotherapy for meningioma prior to 177Lu-
DOTATATE/90Y-DOTATOC   
- number of patients, n [%] 
- Re-irradiation, n [%] 
 
18 [90%] 
7 [35%] 
Chemotherapy prior to 177Lu-DOTATATE/90Y-
DOTATOC   
- number of patients, n [%] 
 
6 [30%] 
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Table 2: Response assessment and outcome 
Meningioma grade prior to 177Lu-
DOTATATE/90Y-DOTATOC  
I II  III  Total 
Number of patients n=5 n=7 n=8 n=20 
Best response     
Partial response 0% 0% 0% 0% 
Stable disease 5 [100%] 4 [57%] 1 [13%] 50% 
Progressive disease  0% 3 [43%] 7 [88%] 50% 
Median PFS [months] 32.2 7.6 2.1 5.4 
PFS-6 100% 57% 0% 42% 
Median OS [months] Not reached Not reached 17.2 Not reached 
OS-12  100% 86% 63% 79% 
 
 28 
 
Table 3: Review of the literature on radionuclide treatment of meningiomas 
Trial design Patients Radionuclide Previous 
treatment 
Best 
response 
Definition of SD Median 
PFS 
PFS-6  OS from 
recruitment 
Intention-to-
treat analysis 
Ref. 
Phase II Progressive 
unresectable 
meningioma, n=34 (5 
WHO I, 6 WHO II, 3 
WHO III, 20 not 
available) 
90Y-
DOTATOC 
and 177Lu-
DOTATOC 
74% 
Surgery 
3% RT   
33% 
Chemo 
 
38% SD <20% increase of 
tumor volume 
(RECIST, CT or 
MRI) 
Not 
available 
Not 
available 
8.6 years 
(mean OS) 
Yes 17 
Phase II Progressive (80%)  or 
unresectable (20%) 
meningioma, 9 WHO 
I, 2 WHO II, 1 WHO 
III,  3 without 
histology 
90Y-
DOTATOC 
66% 
Surgery 
20% RT 
7% Chemo 
87% SD <20% increase of 
tumor volume 
(RECIST, MRI) 
24 
months 
Not 
available 
Not 
available 
Yes 18 
Phase I  SSTR positive tumors,  
n=3 meningiomas 
90Y-
DOTATOC 
Not 
available 
33% CR, 
67% SD 
<50% decrease of 
tumor volume 
(CT), progression 
not defined 
Not 
available 
Not 
available 
Not 
available 
No, exclusion 
of patients not 
receiving 4 
cycles 
20 
Cohort study SSTR positive 
recurrent 
meningiomas, n=29 
(14 WHO I, 9 WHO II, 
6 WHO III)  
90Y-
DOTATOC 
90% 
Surgery 
62% RT 
3.4% 
Chemo 
66% SD <50% increase or 
decrease of lesions 
(SWOG-criteria, 
MRI) 
Not 
available 
46%1 40 months 
(median OS) 
Yes 19 
Retrospective SSTR positive 
meningiomas, n=8  
(5 WHO I, 3 WHO II) 
111In-
Pentetreotide 
74% 
Surgery 
13% RT   
0% Chemo 
 
25% PR, 
63% SD 
<50% increase or 
decrease of lesions 
(SWOG-criteria, 
MRI) 
Not 
available 
Not 
available 
Not 
available 
Yes 21 
Abbreviations: Chemo, chemotherapy; CR, complete response; PFS: Progression-free survival; OS: Overall survival; Ref, Reference; RT, radiotherapy; SD, stable disease; 
SSTR, somatostatin receptor 
1 Calculated from graph 
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Supplementary Table 1: Individual patient characteristics 
ID Age1 Histological Subtype1 WHO
1 Histological subtype2 WHO
2 
Relevant history 
prior to diagnosis of 
meningioma 
Type of 
systemic 
pretreatment 
for 
meningioma 
Dose(s) (Gy) 
and types of 
previous RT 
for 
meningioma 
SSTR 
expression2 
Cycles
3 
Mean 
dose 
/cycle 
(MBq) 
Total 
dose 
(MBq) 
Best 
Response PFS OS FU 
Fig. 
2 
1 35 Transitional I Transitional I None None - Grade 4 4 7339 29354 SD - - 18 - 
2 38 Meningothelial I Anaplastic III None None 
50 (CRT), 17 
(SRT), 17 
(SRT) 
Grade 2 1 7445 7445 PD 1 2 2 - 
3 67 Meningo-thelial I Atypical II None None 
54 (CRT), 17 
(SRT), 50 
(CRT) 
Grade 4 3 7436 22309 SD 13 14 14 - 
4 18 Transitional I Atypical II CRT (18 Gy) for acute lymphatic leukemia None 60 (CRT) Grade 4 4 7425 29699 SD - - 17 - 
5 62 Atypical II Atypical II None None 
54 (CRT), 
53 (CRT) 
Grade 3 4 7443 29711 SD 22 - 31 - 
6 61 n/a I Rhabdoid III None Hydroxyurea 
16.5 (SRS), 
54 (CRT) 
Grade 1 2 7383 14765 PD 2 4 4 - 
7 31 Meningothelial II Atypical II 
Neurofibromatosis 
type II, 60CoRT (dose 
n/a) for pilocytic 
astrocytoma (at age of 
6 years) 
None 54 (CRT) Grade 1 3 7419 22257 PD 6 - 20 - 
8 34 n/a I n/a III None None 
54 (fSRT), 
54 (fSRT) 
n/a 4 7429 29715 PD 5 - 15 - 
9 26 Fibroblastic I Fibroblastic I 
CRT (dose n/a) for 
acute lymphatic 
leukemia (at age of 7 
years) 
None 54 (CRT) Grade 4 4 7443 29772 SD - - 12 - 
104 44 Atypical II Atypical II None 
Hydroxyurea 
Sandostatin 
LAR, 
Bevacizumab 
63 (CRT) Grade 2 2 6660 13320 SD 8 19 19 C 
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ID Age1 Histological Subtype1 WHO
1 Histological subtype2 WHO
2 
Relevant history 
prior to diagnosis of 
meningioma 
Type of 
systemic 
pretreatment 
for 
meningioma 
Dose(s) (Gy) 
and types of 
previous RT 
for 
meningioma 
SSTR 
expression2 
Cycles
3 
Mean 
dose 
/cycle 
(MBq) 
Total 
dose 
(MBq) 
Best 
Response PFS OS FU 
Fig. 
2 
+/- Doxorubicin 
Bevacizumab 
+Etoposid 
115 33 Atypical II Anaplastic III None Bevacizumab +Etoposid 59 (CRT) Grade 1 3 6968 20905
 SD 3 10 10 D 
12 54 Meningothelial I Anaplastic III None Sandostatin LAR 58 (CRT) Grade 4 2 6475 12950 PD 2 17 17 H 
13 35 Meningothelial I Anaplastic III None None 60 (CRT) Grade 4 1 3400 3400 PD 1 - 27 F 
14 49 Meningothelial I Meningothelial I None None 54 (CRT) Grade 3 2 7400 14800 SD 21 - 22 B 
15 62 Clear cell II Clear cell II None Sorafenib 
53 (CRT) 
3x10 (SRS) 
Grade 3 1 7400 7400 PD 2 3 3 - 
16 56 Meningothelial I Meningothelial I None None 54 (CRT) Grade 2 4 5473 21890 SD - - 43 A 
17 41 Meningothelial II Atypical II 
RT (dose n/a) due to 
retinoblastoma (at age 
of 3 months) 
None - n/a 3 6467 19400 PD 4 - 24 - 
18 58 Atypical II Anaplastic III None None 60 (CRT) Grade 1 2 7400 14800 PD 2 - 14 G 
19 65 Atypical II Rhabdoid III None None 63 (CRT) Grade 1 2 7350 14700 PD 4 - 13 E 
20 29 Atypical II Transitional I None None 
50 
(SRT+CRT), 
50 
(SRT+CRT) 
Grade 2 3 7400 22200 SD - - 5 - 
1At time of diagnosis, 2At time of last surgery before radionuclide therapy, 3Cycles of DOTATATE or DOTATOC radionuclide treatment, 4This patient received interferon-alpha-2a during  DOTATOC radionuclide 
treatment, 5This patient received  embolization immediately prior  DOTATOC radionuclide treatment 
Abbreviations: 60CoRT, Cobalt-60 radiotherapy; CRT, conventional radiotherapy; ID, identification number, Fig, Figure; FU, Follow-up in months; OS, overall survival in months; PFS: Progression-free survival in 
months; n/a, not available; RT: radiotherapy; SRS, stereotactic radiosurgery; (f)SRT, stereotactic radiotherapy; SSTR, somatostatin receptor; WHO, World Health Organization grade;
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Supplementary Table 2: Toxicity1 
 CTC grade  Total 
1 2 3 4 
Hematologic      
Anemia 10% 5% - - 10% 
Thrombocytopenia 10% - 5%3 - 5% 
Lymphocytopenia 25% 15% 25% 5% 70% 
Non-hematologic      
Creatinine increase - - - - 0% 
Fatigue 5% - - - 5% 
Alopecia 5% - - - 5% 
Pituitary insufficiency - 5% - - 5% 
Wound complication - - 5% - 5% 
Increase of GGT2 5% 5% - - 10% 
1Analysis for the time period of treatment, e.g. from the first day of treatment until 3 
months after the last treatment 
2Gamma-glutamyl-transpeptidase 
3Probably not related to radionuclide therapy 
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Supplementary Figure 1: Representative SSTR2 immunostains  
Representative images for scoring of SSTR expression according to immunohistochemical 
methods:  Grade 1 (no/weak, A), grade 2 (milde/modest, B), grade 3 (moderate, C) and grade 
4 (strong, D) expression. Scale bar in A corresponds to 100 µm in A-D. 
 
 




